Abstract
Anticholinergic agents have been used for over 100 years for treating Parkinson’s disease and clinical trials have been reported since the late nineteenth century (Aquilonius 1979). In the past two decades more drug studies have been conducted in Parkinson’s disease than in any other neurological disorder.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Armitage P (1957) Restricted sequential procedures. Biometrics 44: 9–26
Armitage P (1960) Sequential medical trials. Blackwell, Oxford
Aquilonius S-M (1979) Cholinergic mechanisms in the CNS related to Parkinson’s disease. In: Rinne UK, Klingler M, Stamm G (eds) Parkinson’s disease current progress, problems and management. Elsevier, North-Holland, Amsterdam, pp 17–27
Barbeau A (1961) Biochemistry of Parkinson’s disease. In: Proceedings of the seventh international congress of neurology, Rome, Sept, Societa Grafica Romana, Rome, vol 2, p 925
Barbeau A (1969) L-Dopa therapy in Parkinson’s disease: a critical review of nine years’ experience. Can Med. Assoc J. 101: 791–800
Barbeau A Roy M (1976) Six-year results of treatment with levodopa plus benzerazide in Parkinson’s disease. Neurology (NY) 267: 399–404
Birkmayer W, Hornykiewicz O (1966) Der L-3,4-Dioxyphenylalanin (=DOPA)-Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 73: 787–788
Birkmayer W, Hornykiewicz O (1962) Der L-Dioxyphenylalanin (= L-DOPA)-Effekt beim Parkinson-Syndrom des Menschen: zur Pathogenese und Behandlung der Parkinson-Akinese. Arch Psychiatr Nervenkr 203: 560–574
Birkmayer W, Riederer P, Ambrozi L, Youdim MBH (1977) Implications of combined treatment with “Madopar” and L-deprenyl in Parkinson’s disease. Lancet 1: 439–443
Calne DB, Teychenne PF, Claveria LE, Eastman R, Greenacre JK, Petrie A (1974). Bromocriptine in parkinsonism. Br Med J 4: 442–444
Canter GJ, deLa Torre R, Mier M (1961) A method for evaluating disability in patients with Parkinson’s disease. J Nerv Ment Dis 133: 143–147
Cotzias GC, Papavasilou PS, Gellene R (1969) Modification of parkinsonism—chronic treatment with L-dopa. N Engl J Med 280: 337–345
Donaldson J, LaBella FS, Gesser D (1980) Enhanced autoxidation of dopamine as a possible basis of manganese neurotoxicity. Neurotoxicology (Park Forest II ) 2: 53–64
Duvoisin RC (1970) The evaluation of extra-pyramidal disease. In: de Ajuriagerra J (ed) Monoamines: noyaux gris centraux et syndrome de Parkinson. Masson, Paris, pp 313–325
Eisler T, Thorner MO, MacLeod RM, Kaiser DL, Calne DB (1981) Prolactin secretion in Parkinson’s disease. Neurology (NY) 31: 1356–1359
England AC, Schwab RS (1956) Post-operative evaluation of selected patients with Parkinson’s disease. J Am Geriatr Soc 4: 1219–1232
Evarts EV, Teravainen H, Calne DB (1981) Reaction time in Parkinson’s disease. Brain 106: 167–186
Fienbery SE (1983) The analysis of cross-classified categorial data, 2nd edn. MIT Press, Cambridge
Folkerts JF, Njiokiktjien CJ (1971) The influence of L-dopa on the postural regulation of Parkinson patients. 1st Symposium international de posturographie, Madrid, 19–22 Oct
Hietanen M, Teravainen H, Tsui JK, Calne DB (1987) The pegboard as a measurement of parkinsonian motor deficit. Neurology 37 (Suppl 1): 266
Hoaglin DC, Mosteller F, Tukey JW (1983) Understanding robust and exploratory data analysis. Wiley, New York
Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology (NY) 17: 427–442
Jansen EC, Larsen RE, Olesen MB (1982) Quantitative Romberg’s test. Acta Neurol Scand 66: 93–99
Kartzinel R, Perlow MD, Carter AC, Chase TN, Calne DB, Shoulson I (1976) Metabolic studies with bromocriptine in patients with idiopathic parkinsonism and Huntington’s chorea. Trans Am Neurol Assoc 101: 53–56
Knopp W (1968) Explorations in the assessment and meaning of the subclinical extrapyramidal effect of neuroleptic drugs. Pharmakopsychiatria Neuropsychopharmakol 1: 54–62
Knutsson E (1972) An analysis of parkinsonian gait. Brain 95: 475–486
Lakke JPWF, Korf J, Van Praag HM, Schut T (1972) Predictive value of the probenecid test for the effect of L-dopa therapy in Parkinson’s disease. Nature New Biol 236: 208–209
Larsen TA, LeWitt PA, Calne DB (1983) Theoretical and practical issues in assessment of deficits and therapy in parksinsonism. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 363–373
Larsen TA, Calne S, Calne DB (1984) Assessment of Parkinson’s disease. Clin Neuropharmacol 7 (2): 165–169
Lieberman A, Dziatolowski M, Gopinathan G, Kupersmith M, Neophytides A, Korein J (1980) Evaluation of Parkinson’s disease. In: Goldstein M, Calne DB, Lieberman A, Thorner MO (eds) Ergot compounds and brain function: neuroendocrine and neuropsychiatric aspects. Raven, New York, pp 277–286
Lyman O (1984) An introduction to statistical methods and data analysis, 2nd ed Duxbury, Boston
Markham CH, Diamond SG (1981) Evidence to support early levodopa therapy in Parkinson’s disease. Neurology (NY) 31: 125–131
Martin WRW, Stoessl AJ, Adam MJ, Ammann W, Bergstrom M, Harrop R, Laihinen A, Rogers JG, Ruth TJ, Sayre CI, Pate BD, Calne DB (1986) Positron emission tomography in Parkinson’s disease: glucose and DOPA metabolism. Adv Neurol 45: 95–101
Parkes JD, Curzon G, Knott PJ, Tattersall R, Baxter RCH, Knill-Jones RP, Marsden CD, Vollum D (1971) Treatment of Parkinson’s disease with amantadine and levodopa. Lancet 1: 1083–1086
Schoenberg BS, Anderson DW, Haerer AF (1986) Racial differentials in the prevalence of Parkinson’s disease. Neural 36: 841–845
Shoulson I, The Parkinson Sindy Group (1987). Correlates of clinical decline in early Parkinson’s disease (ABST). Neurology 37 (Suppl 1): 278
Stoessl AJ, Mak E, Calne DB (1985) (+)-4-propyl-9-hydroxynaphthoxazine ( PHNO), a new dopaminomimetic, in treatment of parkinsonism. Lancet ii: 1130–1331
Tatton WG, Eastman MJ, Bedingham W, Verrier MC, Bruce IC (1984) Defective utilization of sensory input as the basis for bradykinesia, rigidity and decreased movement repertoire in Parkinson’s disease: a hypothesis. Can J Neurol Sci 11: 136–143
Teräväinen H, Calne DB (1980) Quantitative assessment of Parkinsonian deficits. In: Rinne UK, Klingler M, Stamm G (eds) Parkinson’s disease: current progress, problems and management. Elsevier, North-Holland, Amsterdam, pp 145–164
Teräväinen H, Evarts EV, Calne DB (1980) Studies of parkinsonian movement. 1. Programming and execution of eye movements. Acta Neurol Scand 62: 137–148
Wagner HN, Burns HD, Dannais RF, Wong DF, Langstrom B, Duelfer T, Frost JJ, Ravart HT, Links JM, Rosenbloom SB, Lukas SE, Kramer AV, Kuhar MJ (1983) Imaging dopamine receptors in the human brain by positron tomography. Science 221: 264–1266
Ward CD, Sanes JN, Dambrosia JM, Calne DB (1983) Methods for evaluating treatment in Parkinson’s disease. Adv Neurol 37: 1–7
Webster DD (1968) Critical analysis of the disability in Parkinson’s disease. Mod Treat 5: 257–282
Webster DD, Mortimer JA (1977) Failure of L-dopa to relieve activated rigidity in Parkinson’s disease. In: Messiha FS, Kenny AD (eds) Parkinson’s disease. Neurophysiological, clinical and related aspects, Plenum, New York, pp 297–313.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Tsui, J.K., Teräväinen, H., Calne, D.B. (1989). Clinical Trials for Parkinson’s Disease. In: Calne, D.B. (eds) Drugs for the Treatment of Parkinson’s Disease. Handbook of Experimental Pharmacology, vol 88. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73899-9_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-73899-9_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73901-9
Online ISBN: 978-3-642-73899-9
eBook Packages: Springer Book Archive